GlassScriptPhysician profile
Prakash N Shah
NPI 1902803513
$1,914.28
in general payments reported to CMS, 2019-2025
27 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.60 · 2020: $186 · 2021: $155 · 2022: $345 · 2023: $309 · 2024: $520 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856 · Travel and Lodging: $241 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.54 |
| Travel and Lodging | $240.74 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $470.84 | 2020-2025 | Breztri, Tagrisso, Farxiga |
| Medtronic, INC. | $240.74 | 2024 | |
| Neurocrine Biosciences, INC. | $220.98 | 2024-2025 | Ingrezza |
| Galderma Laboratories, L.P. | $133.41 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.06 | 2020-2021 | |
| Amgen INC. | $101.76 | 2019-2022 | |
| Janssen Biotech, INC. | $72.00 | 2025 | Tremfya |
| Otsuka America Pharmaceutical, INC. | $70.28 | 2021-2025 | Nuedexta, Rexulti |
| Novartis Pharmaceuticals Corporation | $68.04 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $46.67 | 2023-2024 | Sotyktu |
| Novo Nordisk INC | $43.14 | 2020-2025 | |
| Allergan, INC. | $35.15 | 2019 | |
| Merck Sharp & Dohme LLC | $33.72 | 2023 | Verquvo |
| Pfizer INC. | $32.04 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $26.14 | 2020-2025 | Zoryve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $21.90 | 2020 | |
| Insulet Corporation | $21.23 | 2025 | Omnipod |
| Lundbeck LLC | $20.65 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.52 | 2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $18.61 | 2025 | Fanapt |
| Abbvie INC. | $18.16 | 2022 | |
| Phadia US INC. | $17.94 | 2023 | Immunocap |
| Astellas Pharma US INC | $17.16 | 2022 | |
| Inspire Medical Systems, INC. | $15.38 | 2025 | Inspire |
| Esperion Therapeutics, INC. | $14.82 | 2020 | |
| Amarin Pharma, INC. | $14.14 | 2021 | |
| Lilly USA, LLC | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prakash Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.